Features include very common findings: Low white blood cell count (decreased total leukocyte count), Decreased total lymphocyte count, Elevated antibody levels (increased circulating immunoglobulin concentration), and Viremia and others; and common findings: Abnormal bleeding tendency (abnormal bleeding), Increased immature red blood cells (reticulocytosis), Fever, and Vomiting and others. 74 total HPO annotations.

Biomarker and diagnostic research for Marburg hemorrhagic fever has been reported in the published literature.

No approved treatments are currently available for Marburg hemorrhagic fever. An additional 1 compound holds orphan drug designation.

Orphan Drug Designations

While no drugs are FDA-approved specifically for Marburg hemorrhagic fever, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.

The following drugs have received orphan drug designation from the FDA for Marburg hemorrhagic fever. Orphan designation reflects regulatory interest and does not indicate approval for treatment.

Phenotype severity distribution: 5 very common features, 16 common features.

Estimated prevalence: <1 in 1,000,000 (VERY_RARE).

2 clinical trials registered, 1 recruiting. Interventions under study include biologic therapy and other interventions. Pipeline includes 1 PHASE2, 1 PHASE1. Research is primarily sponsored by academic and government institutions.

147 publications have been identified in PubMed for Marburg hemorrhagic fever. Research spans Epidemiology / Natural History (37%), Review / Meta-Analysis (17%), and Gene Therapy / Novel Therapeutics (16%).